Sanofi/GSK COVID Vaccine Hits Major Hurdle As It Fails To Work in Elderly Patients

Sanofi and GSK announced their experimental COVID vaccine candidate failed in some older patients.



French multinational pharmaceutical company Sanofi and Britain’s GSK announced on Friday their coronavirus vaccines will not be ready until the end of 2021. The announcement comes as the pharmaceutical industry leaders’ interim results showed their COVID vaccine had failed to produce a strong immune response in older adults.

Hours earlier it was reported that the Australian government has scrapped its homegrown COVID-19 vaccine after the inoculation produced false positive test results in several trial participants.

The announcements signal a major setback in the progress made so far to fight the coronavirus outbreak, which emerged in Wuhan, China last December and has killed over 1.5 million people worldwide.

Sanofi and GSK said the delay in their adjuvanted COVID-19 vaccine program was to improve immune response in the elderly. GSK had previously announced that it expected regulatory approvals in the first half of 2021. The vaccine’s availability has now been pushed back from mid-2021 to Q4 2021.

The world of vaccine development is fraught with possibilities for failure. Even the most optimistic analysts would not have expected pharmaceutical companies to develop a highly effective vaccine against a new virus in less than twelve months after its genome was sequenced.

The announcements that came today are a strong reminder of the difficulties of developing vaccines at breakneck speed.

COVID vaccine development Sanofi and GSK

Sanofi and GSK had previously announced that it expected regulatory approvals in the first half of 2021. The vaccine’s availability has now been pushed back from mid-2021 to Q4 2021.

COVID Vaccine Studies Postponed

The adjuvanted recombinant protein-based vaccine candidate, developed by Sanofi in partnership with GSK, is based on technology that Sanofi has used to produce seasonal influenza vaccines and on immunological agents developed by GSK. The companies planned to conduct further studies with an improved antigen formulation.

The European Union has ordered 300 million doses of the Sanofi/GSK coronavirus vaccine while the UK has asked for 60 million doses. Back home, the U.S. government has ordered an initial 100 million doses plus an option for 500 million.

COVAX, a global initiative aimed at speeding up the development, manufacture and equitable distribution of new vaccines, was to receive 200 million.

The pharmaceutical giants were disappointed by the hiccup.

Roger Connor, President of GSK Vaccines said: “The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile. It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19.”

Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

Monte dei Paschi performance below par in EU banks stress test

Monte dei Paschi performance below par in EU banks stress test

The depletion of capital at each bank under the test’s harshest scenario will be closely scrutinised, and could potentially lead to hostile takeovers
2 days ago
Nokia to launch T20 tablet with 10.36 inch display

Nokia to launch T20 tablet with 10.36 inch display

The Nokia T20 will sport a 10.36-inch display and will have 4 GB RAM along with 64 gigs of native storage.
3 days ago
Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

Ford sees surprise Q2 profit despite chip shortage and manufacturing hassles

“The business is ‘spring loaded’ for a rebound when semiconductor supplies stabilize and more closely match demand.”
4 days ago
Audi A6 E-tron Production Launch in 2023

Audi A6 E-tron Production Launch in 2023

Audi has confirmed that there will be multiple variants of the etron, including “basic versions optimized for minimum consumption and maximum range.
4 days ago
Royal Dutch Shell buyback lifts investor sentiment

Royal Dutch Shell buyback lifts investor sentiment

Royal Dutch Shell commences share buybacks before the end of this year while reducing its first quarter dividend to 16 cents per share, a 66% cut.
4 days ago
Citizens Financial to acquire Investors Bancorp in $3.5 billion NYC push

Citizens Financial to acquire Investors Bancorp in $3.5 billion NYC push

Citizens Financial Group, Inc. and Investors Bancorp announced today that they have entered into a definitive agreement and plan of merger in a cash-and-stock deal worth $3.5 billi
5 days ago